Metastatic prostate cancer remains to this day a terminal disease.
Prostatectomy and radiotherapy are effective for organ-confined diseases, but treatment for locally advanced and metastatic cancer remains challenging. Although advanced prostate cancers treated with androgen deprivation therapy achieves debulking of disease, responses are transient with subsequent development of castration-resistant and metastatic disease. Since prostate cancer is typically a slowly progressing disease, use of immune-based therapies offers an advantage to target advanced tumors and to induce antitumor immunity. This review will discuss the clinical merits of various vaccines and immunotherapies in castrate resistant prostate cancer and challenges to this evolving field of immune-based therapies.
Written by:
Thakur A, Vaishampayan U, Lum LG. Are you the author?
Department of Oncology, Wayne State University, Detroit, MI 48201, USA.
Reference: Cancers (Basel). 2013 May 24;5(2):569-90.
doi: 10.3390/cancers5020569
PubMed Abstract
PMID: 24216992
UroToday.com Prostate Cancer Immunotherapy Section
